Anti mir 1271 5p

siRNA targeting MALAT1 (si-MALAT1#1 and si-MALAT1 #2), siRNA negative control (si-NC), pcDNA, and E2F5 were bought from Genepharma (Shanghai, China). miR-1271-5p mimics (miR-1271-5p) and miR-NC, and miR-1271-5p inhibitor (anti-miR-1271-5p) and anti-miR-NC were purchased from RIBOBIO (Guangzhou, China). Cell transfection was performed using Lipofectamine 3000 (Invitrogen).

To mimic HBV infection, a plasmid with 1.3 mer HBV genomic DNA (pcDNA3.1-1.3 mer) was transfected into Huh7 cells using FuGENE^® HD Transfection reagent (Promega Corporation), thus generating the HBV-HCC cell line Huh7-1.3. miR-1271-5p mimic (miR-1271-5p; 40 nM; 5′-CUUGGCACCUAGCAAGCACUCA-3′) or miR-1271-5p inhibition (anti-miR-1271-5p; 60 nM; 5′-UGAGUGCUUGCUAGGUGCCAAG-3′) and their corresponding control miR-negative control (NC) or anti-miR-NC were purchased from Guangzhou RiboBio Co., Ltd. The small interference (si)RNA against AQP5 (si-AQP5; 2.5 µg; 5′-GACAGACUGGUUCAUUGAAUG-3′), the scrambled siRNA (Scramble; 2.5 µg), pcDNA3.1-AQP5 (AQP5; 1 µg) and pcDNA3.1 empty vector (vector; 1 µg) were all obtained from Shanghai GenePharma Co., Ltd. These transfection assays were conducted using Lipofectamine^® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Blank transfection served as the control. The experiments described below were performed at 48 h after transfection.